Clinical outcomes of allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in the tyrosine kinase inhibitor era

DOI Web Site 1 Citations 18 References Open Access
  • Kawashima Masaharu
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Yano Shingo
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Saito Takeshi
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Yokoyama Hiroki
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Machishima Tomohito
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Shimada Takaki
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Yahagi Yuichi
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Ogasawara Yoji
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Sugiyama Katsuki
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Takahara Shinobu
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Minami Jiro
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Kamiyama Yutaro
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Katsube Atsushi
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Suzuki Kazuhito
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine
  • Dobashi Nobuaki
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University Daisan Hospital
  • Usui Noriko
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University Daisan Hospital
  • Aiba Keisuke
    Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine

Bibliographic Information

Other Title
  • チロシンキナーゼ阻害薬時代の慢性骨髄性白血病に対する同種造血幹細胞移植の治療成績

Search this article

Description

<p> We retrospectively analyzed the outcomes of 14 patients with chronic myeloid leukemia (CML) who underwent allogeneic hematopoietic stem cell transplantation in the tyrosine kinase inhibitor (TKI) era. The median age of the patients was 42 years (range, 20-66 years). Disease status at transplantation was as follows: first chronic phase (CP1; n=3), second chronic phase (CP2; n=8), and accelerated phase/blast phase (AP/BP; n=3). Sources of stem cells were as follows: related bone marrow (BM; n=2), related peripheral blood stem cells (n=1), unrelated BM (n=4), and cord blood (n=7). The 3-year overall survival (OS) rate was 71%. According to the disease status at the time of transplantation, the 3-year OS rate was 67% in CP1, 75% in CP2, and 67% in AP/BP (P=0.925). The six patients newly diagnosed with BP CML achieved CP2, and the 3-year OS rate was 83%. In the TKI era, patients newly diagnosed with BP CML are expected to demonstrate improved prognosis.</p>

Journal

Citations (1)*help

See more

References(18)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top